BIBLIOGRAPHIE : Beta-Carbolines Harmine, Harmane, Harmaline, Nor-harmane, Harmol, Harmalol, Tetrahydroharmine β-Carbolines et Thérapeutique en Psychiatrie, p. 6. (cf également Bibliographie : Peganum harmala, p. 7 ci-dessous, et Bibliographie : Amanita muscaria, et Bibliographie : Ayahuasca) Dr Christian SUEUR, GRECC, décembre 2019.
Lire la suitePsychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This : Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too) An Interview with Richard Yensen Philip E. Wolfson International Journal of Transpersonal Studies, 2014, 33, (2), 160-174. Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from 1972 to 1976. He studied psychedelic psychotherapy with Stanislav Grof, M.D. and other senior staff. During this time he treated patients with substance abuse disorders, cancer, neurosis, and other health professionals seeking a training experience. Dr. Yensen did his Ph.D. dissertation on the use of MDA in [...]
Lire la suiteModulation of Social Cognition via Hallucinogens and “Entactogens” Katrin H. Preller and Franz X. Vollenweider Frontiers in Psychiatry, décembre 2019 doi: 10.3389/fpsyt.2019.00881 Social cognition is a fundamental ability in human everyday lives. Deficits in social functioning also represent a core aspect of many psychiatric disorders. Yet, despite its significance, deficits in social cognition skills are insufficiently targeted by current treatments. Hallucinogens and entactogens have been shown to have the potential to modulate social processing. This article reviews the literature on the influence of hallucinogens and entactogens on social processing in controlled experimental studies in humans and elucidates the underlying neurobiological and neuropharmacological mechanisms. Furthermore, [...]
Lire la suitePsychedelics and music : neuroscience and therapeutic implications Frederick S. Barrett, Katrin H. Preller & Mendel Kaelen International Review of Psychiatry, 2018 https://doi.org/10.1080/09540261.2018.1484342 ABSTRACT From the beginning of therapeutic research with psychedelics, music listening has been consistently used as a method to guide or support therapeutic experiences during the acute effects of psychedelic drugs. Recent findings point to the potential of music to support meaning-making, emotionality, and mental imagery after the administration of psychedelics, and suggest that music plays an important role in facilitating positive clinical outcomes of psychedelic therapy. This review explores the history of, contemporary research on, and future directions regarding the use [...]
Lire la suiteMolecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites Chun Yang, Jianjun Yang, Ailin Luo and Kenji Hashimoto Translational Psychiatry, 2019, 9, 280 doi : 10.1038/s41398-019-0624-1 Abstract Although the robust antidepressant effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although (R)-ketamine is a less potent NMDAR antagonist than (S)-ketamine, (R)-ketamine has shown more marked and longer-lasting antidepressant-like [...]
Lire la suiteCBD & the Psychedelic Receptor Lex Pelger On March 11, 2018 (Updated on April 16, 2019) https://www.projectcbd.org/science/cbd-psychedelic-receptor CBD and LSD bind to the same serotonin receptor, which mediates psychedelic altered states. But cannabidiol has anti-psychotic properties and doesn't cause hallucinations. In a shorthand that drives scientists mad, serotonin is often called ‘the neurotransmitter of happiness.’ This tag is especially troublesome as more and more flaws become apparent in the ‘serotonin hypothesis’ of depression – the idea that depression is caused by a serotonin deficit, which a pill (a serotonin reuptake inhibitor) could correct.1 Serotonin is a complex molecule in the brain and the [...]
Lire la suitePsychedelics & Cannabis Therapeutics Martin A. Lee April 17, 2019 https://www.projectcbd.org/culture/psychedelics-cannabis-therapeutics High doses of THC are hallucinogenic, and microdosing LSD is a lot like CBD. These mighty molecules can relieve human suffering and they act through the endocannabinoid system. Although it may not be obvious during these Trump-rattled times, we’re in the midst of a psychedelic revival. There is more interest than ever before in experimenting with LSD, magic mushrooms, ayahuasca, ketamine, and other psychedelic drugs. This renaissance is happening without all the fanfare of the day-glo Sixties, when lysergic acid diethylamide (LSD) escaped from the laboratory and assumed the lead role in an improbable [...]
Lire la suiteDMT Research from 1956 to the Edge of Time Andrew R. Gallimore and David P. Luke Originally published as Gallimore, A., & Luke, D. : DMT research from 1956 to the edge of time. In King, D., Luke, D., Sessa, B., Adams, C. & Tollen, A. (Eds.), Neurotransmissions : Essays on Psychedelics from Breaking Convention (pp.291-‐316). London: Strange Attractor. (2015).
Lire la suiteThe DMT Gland : The Pineal, The Spirit Molecule, and Popular Culture Graham St John International Journal for the Study of New Religions, 7.2 , 2016, 153–174 ISSN 2041-9511 (print) ISSN 2041-952X (online) 10.1558/ijsnr.v7i2.31949 With clinical psychiatrist Rick Strassman’s DMT: The Spirit Molecule as a vehicle, the pineal gland has become a popularly enigmatic organ that quite literally excretes mystery. Strassman’s top selling book documented groundbreaking clinical trials with the powerful mind altering compound DMT (N,N-dimethyltryptamine) conducted at the University of New Mexico in the early 1990s. Inflected with Buddhist metaphysics, the book proposed that DMT secreted from the pineal gland enables transit of the [...]
Lire la suiteLa FDA accélère la recherche sur la psilocybine pour les troubles dépressifs majeurs Aurélien Bernard Newsweed, 28 novembre 2019 https://www.newsweed.fr/fda-accelere-recherche-psilocybine-depression/ La Food and Drug Administration (FDA) a catégorisé les champignons hallucinogènes en tant que « thérapie révolutionnaire » pour les troubles dépressifs majeurs (MDD), une démarche qui accélérera la recherche de nouveaux médicaments à partir de psilocybine. Cette classification a été créée en 2012 pour encadrer les recherches et le développement produit de médicaments à partir de susbtances ayant un potentiel fort par rapport aux options existantes et pour des patients atteints de maladie grave ou qui met leur vie en danger. La première recherche [...]
Lire la suite